Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Neurotherapeutics ; 19(5): 1546-1565, 2022 09.
Article in English | MEDLINE | ID: mdl-35917087

ABSTRACT

Abnormal productions of amyloid beta (Aß) plaque and chronic neuroinflammation are commonly observed in the brain of patients with Alzheimer's disease, and both of which induce neuronal cell death, loss of memory, and cognitive dysfunction. However, many of the drugs targeting the production of Aß peptides have been unsuccessful in treating Alzheimer's disease. In this study, we identified synthetic novel peroxisome proliferator-activating receptor (PPAR) agonist, DTMB, which can ameliorate the chronic inflammation and Aß pathological progression of Alzheimer's disease. We discovered that DTMB attenuated the proinflammatory cytokine production of microglia by reducing the protein level of NF-κB. DTMB also improved the learning and memory defects and reduced the amount of Aß plaque in the brain of 5xFAD mice. This reduction in Aß pathology was attributed to the changes in gliosis and chronic inflammation level. Additionally, bulk RNA-sequencing showed that genes related to inflammation and cognitive function were changed in the hippocampus and cortex of DTMB-treated mice. Our findings demonstrate that DTMB has the potential to be a novel therapeutic agent for Alzheimer's disease.


Subject(s)
Alzheimer Disease , Receptors, Artificial , Mice , Animals , Alzheimer Disease/drug therapy , Alzheimer Disease/genetics , Alzheimer Disease/metabolism , Microglia/metabolism , Amyloid beta-Peptides/metabolism , Peroxisome Proliferator-Activated Receptors/metabolism , Peroxisome Proliferator-Activated Receptors/pharmacology , Peroxisome Proliferator-Activated Receptors/therapeutic use , Mice, Transgenic , NF-kappa B/metabolism , Peroxisome Proliferators/metabolism , Peroxisome Proliferators/pharmacology , Peroxisome Proliferators/therapeutic use , Receptors, Artificial/metabolism , Receptors, Artificial/therapeutic use , Disease Models, Animal , Plaque, Amyloid/metabolism , Inflammation/drug therapy , Inflammation/metabolism , Cytokines/metabolism , RNA/metabolism , RNA/pharmacology , RNA/therapeutic use
2.
COPD ; 13(2): 196-202, 2016.
Article in English | MEDLINE | ID: mdl-26552490

ABSTRACT

Mucosal-associated invariant T (MAIT) cells have been reported to play an important role in mucosal immunity. However, little is known about the roles of MAIT cells in chronic obstructive pulmonary disease (COPD). The aims of this study were to examine the levels of circulating MAIT cells and their subsets in COPD patients and to investigate the potential relationship between clinical parameters and MAIT cell levels. Forty-five COPD patients and 57 healthy control subjects were enrolled in the study. Circulating MAIT cells and their subset levels in the peripheral blood were measured by flow cytometry. Disease grades were classified according to the GOLD criteria for the assessment of severity of COPD. Circulating MAIT cell levels were found to be significantly reduced in COPD patients. In particular, this MAIT cell deficiency was more prominent in CD8+ and double-negative T cell subsets. Interestingly, elevated serum C-reactive protein level and reduced FEV1/FVC ratio were associated with MAIT cell deficiency in COPD patients. Furthermore, the circulating MAIT levels were found to be significantly lower in patients with moderate to severe COPD than in patients with mild COPD. Our data shows that MAIT cells are numerically deficient in the peripheral blood of patients with COPD. In addition, this MAIT cell deficiency was found to reflect inflammatory activity and disease severity. These findings provide important information for monitoring the changes in MAIT cell levels and for predicting the prognosis during the disease course.


Subject(s)
Immunity, Mucosal , Mucosal-Associated Invariant T Cells/immunology , Pulmonary Disease, Chronic Obstructive/immunology , T-Lymphocyte Subsets/immunology , Aged , C-Reactive Protein/metabolism , Cytokines/metabolism , Female , Flow Cytometry , Humans , Male , Middle Aged , Pilot Projects , Pulmonary Disease, Chronic Obstructive/diagnosis , Pulmonary Disease, Chronic Obstructive/metabolism
3.
Arthritis Rheumatol ; 67(10): 2639-50, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26097058

ABSTRACT

OBJECTIVE: To investigate the role played by natural killer T (NKT) cells in osteoclastogenesis and their effects on inflammatory bone destruction. METHODS: Patients with rheumatoid arthritis (RA) (n = 25) and healthy controls (n = 12) were enrolled in this study. In vitro osteoclastogenesis experiments were performed using peripheral blood mononuclear cells (PBMCs) in the presence of macrophage colony-stimulating factor and RANKL. PBMCs were cultured in vitro with α-galactosylceramide (αGalCer), and proliferation indices of NKT cells were estimated by flow cytometry. In vivo effects of αGalCer-stimulated NKT cells on inflammation and bone destruction were determined in mice with collagen-induced arthritis. RESULTS: In vitro osteoclastogenesis was found to be significantly inhibited by αGalCer in healthy controls but not in RA patients. Proliferative responses of NKT cells and STAT-1 phosphorylation in monocytes in response to αGalCer were impaired in RA patients. Notably, αGalCer-stimulated NKT cells inhibited osteoclastogenesis mainly via interferon-γ production in a cytokine-dependent manner (not by cell-cell contact) and down-regulated osteoclast-associated genes. Mice treated with αGalCer showed less severe arthritis and reduced bone destruction. Moreover, proinflammatory cytokine expression in arthritic joints was found to be reduced by αGalCer treatment. CONCLUSION: This study primarily demonstrates that αGalCer-stimulated NKT cells have a regulatory effect on osteoclastogenesis and a protective effect against inflammatory bone destruction. However, it also shows that these effects of αGalCer are diminished in RA patients and that this is related to NKT cell dysfunction. These findings provide important information for those searching for novel therapeutic strategies to prevent bone destruction in RA.


Subject(s)
Arthritis, Experimental/physiopathology , Arthritis, Rheumatoid/physiopathology , Natural Killer T-Cells/physiology , Osteitis/physiopathology , Osteoclasts/physiology , Osteogenesis/physiology , Adult , Aged , Animals , Arthritis, Experimental/pathology , Arthritis, Rheumatoid/pathology , Case-Control Studies , Cell Proliferation/drug effects , Cells, Cultured , Disease Models, Animal , Female , Galactosylceramides/pharmacology , Humans , In Vitro Techniques , Interferon-gamma/metabolism , Male , Mice , Mice, Inbred DBA , Middle Aged , Natural Killer T-Cells/drug effects , Natural Killer T-Cells/pathology , Osteitis/pathology , Osteoclasts/drug effects , Osteoclasts/pathology , Osteogenesis/drug effects , Phosphorylation/drug effects , STAT1 Transcription Factor/metabolism
4.
Tuberculosis (Edinb) ; 95(3): 267-74, 2015 May.
Article in English | MEDLINE | ID: mdl-25837440

ABSTRACT

Mucosal-associated invariant T (MAIT) cells contribute to protection against certain microorganism infections. The aims of this study were to examine the levels of MAIT cells in pulmonary tuberculosis (TB) and nontuberculous mycobacteria (NTM) lung disease patients, to evaluate the clinical relevance of MAIT cell levels, and to investigate the functions of MAIT cells. Patients with pulmonary TB (n = 35), NTM (n = 29), and healthy controls (n = 75) were enrolled in the study. MAIT cell levels and functions were measured by flow cytometry. Circluating MAIT cell levels were found to be reduced in TB and NTM patients. MAIT cell deficiency reflects a variety of clinical conditions. In particular, MAIT cell numbers were significantly correlated with sputum AFB positivity, extent of disease, hemoglobin levels, lymphocyte counts, CRP and ESR levels. MAIT cells in TB patients failed to produce interferon-γ irrespective of the mode of stimulation, whereas NTM patients displayed a defect in MR1-dependent signaling pathway. Notably, an elevated expression of programmed death-1 was also associated with MAIT cell deficiency in TB. This study shows that MAIT cells are numerically and functionally deficient in TB and NTM patients and these deficiencies could contribute to immune system dysreguation in mycobacterial infection.


Subject(s)
Immunity, Mucosal , Mycobacterium Infections, Nontuberculous/immunology , Mycobacterium tuberculosis/immunology , T-Lymphocytes/immunology , Tuberculosis, Pulmonary/immunology , Aged , Case-Control Studies , Cell Line , Female , Flow Cytometry , Humans , Interferon-gamma/immunology , Interferon-gamma/metabolism , Interferon-gamma Release Tests , Lymphocyte Count , Male , Middle Aged , Mycobacterium Infections, Nontuberculous/diagnosis , Mycobacterium Infections, Nontuberculous/metabolism , Mycobacterium Infections, Nontuberculous/microbiology , Predictive Value of Tests , Programmed Cell Death 1 Receptor/metabolism , Sputum/microbiology , T-Lymphocytes/metabolism , T-Lymphocytes/microbiology , Tuberculosis, Pulmonary/diagnosis , Tuberculosis, Pulmonary/metabolism , Tuberculosis, Pulmonary/microbiology
5.
Rheumatol Int ; 34(12): 1711-20, 2014 Dec.
Article in English | MEDLINE | ID: mdl-24816858

ABSTRACT

Triggers of indeterminate results from interferon-gamma release assays (IGRA) in patients with rheumatic diseases are still elusive. The aim of the present study was to describe predictors of indeterminate results from IGRA in the field of rheumatology. This cross-sectional study was retrospectively performed by using a database of patients with a request for QuantiFERON-TB Gold-In Tube test (QFT-GIT) for screening of latent tuberculosis infection. The study cohort included 631 patients with rheumatic diseases. All variables influencing indeterminate QFT-GIT results were investigated by logistic regression analysis. The overall frequency of indeterminate IGRA results was 6.8 % (43/631). Those with indeterminate results were more likely to be aged ≥70 years, female, visitors in winter, suffering from systemic lupus erythematosus (SLE), and using sulfasalazine or a tumor necrosis factor (TNF)-α inhibitor. In addition, a longer incubation time of >6 h increased the odds ratio of indeterminate IGRA results. In contrast, the automated ELISA processor, ankylosing spondylitis, and the use of a non-steroidal anti-inflammatory drug decreased the likelihood of indeterminate IGRA results. Lymphopenia, thrombocytopenia, anemia, and hypoalbuminemia were significantly associated with indeterminate IGRA results. Multivariate analysis revealed that SLE, use of sulfasalazine or a TNF-α inhibitor, and a manual ELISA system were significantly independent predictors of indeterminate IGRA results. The proportion of indeterminate results in patients with rheumatic diseases is not infrequent. Careful attention to the pre-analytical conditions should minimize the indeterminate results. Automation of the ELISA process seems to be a promising solution to decrease the rate of indeterminate response.


Subject(s)
Enzyme-Linked Immunosorbent Assay , Interferon-gamma Release Tests , Interferon-gamma/blood , Latent Tuberculosis/diagnosis , Rheumatic Diseases/diagnosis , Adult , Aged , Automation, Laboratory , Biomarkers/blood , Cross-Sectional Studies , Databases, Factual , Enzyme-Linked Immunosorbent Assay/instrumentation , Enzyme-Linked Immunosorbent Assay/methods , Female , Humans , Interferon-gamma Release Tests/instrumentation , Interferon-gamma Release Tests/methods , Latent Tuberculosis/blood , Latent Tuberculosis/immunology , Logistic Models , Male , Middle Aged , Multivariate Analysis , Odds Ratio , Predictive Value of Tests , Reproducibility of Results , Retrospective Studies , Rheumatic Diseases/blood , Rheumatic Diseases/immunology , Risk Factors
7.
Biomaterials ; 34(38): 9747-53, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24055522

ABSTRACT

An epidermal growth factor (EGF) derivative with affinity for apatite and titanium surfaces was designed using a peptide moiety derived from salivary statherin, a protein that adheres to hydroxyapatite. Since the active sequence has two phosphoserine residues, the EGF derivative was prepared by organic synthesis, and a 54 residue peptide was successfully prepared using this method. Circular dichroism spectra indicated that the conformation of EGF was not significantly altered by the addition of the affinity peptide sequence and the mitogenic activity was only slightly reduced when compared with the wild-type protein. However, the binding affinity of the modified EGF to hydroxyapatite and titanium was significantly higher than the unmodified EGF. The phosphate groups in the affinity sequence contributed to the affinity of modified EGF to both apatite and titanium. The modified EGF significantly enhanced the growth of cells on hydroxyapatite and titanium. It was also demonstrated that the bound EGF enhanced the signal transduction for longer periods than unbound EGF. In conclusion, the modified EGF had significantly higher binding affinity for apatite and titanium than soluble EGF, and the bound EGF significantly enhanced cell growth by long-lasting activation of intracellular signal transduction.


Subject(s)
Durapatite/chemistry , Epidermal Growth Factor/chemistry , Titanium/chemistry , Animals , Biocompatible Materials/chemistry , Cell Line , Circular Dichroism , Rats
8.
Acta Biomater ; 9(5): 6753-61, 2013 May.
Article in English | MEDLINE | ID: mdl-23333442

ABSTRACT

Dopamine, an adhesive protein can be covalently deposited onto biomaterials. In this study, we evaluated the ability of dopamine-coated surfaces for small interfering RNA (siRNA) immobilization and release. Dopamine was deposited onto 316L stainless steel discs either as a monolayer at acidic pH or as polydopamine at alkaline pH, following which siRNA was immobilized onto these discs. To investigate the RNA interference ability of immobilized siRNA, reduction of luciferase expression in HeLa, and reduction of Egr-1 expression and cell proliferation in human aortic smooth muscle cells (HAoSMCs) were determined. Dopamine treatment of 316L stainless steel discs under both the acidic and alkaline conditions resulted in the deposition of amino (NH2) groups, which enabled electrostatic immobilization of siRNA. The immobilized siRNA was released from both types of coatings, and enhanced the percent suppression of firefly luciferase activity of HeLa significantly up to ~96.5% compared to HeLa on non-dopamine controls (18%). Both the release of siRNA and the percent suppression of firefly luciferase activity were sustained for at least 7 days. In another set of experiments, siRNA sequences targeting to inhibit the activity of the transcription factor Egr-1 were eluted from dopamine-coated surfaces to HAoSMCs. Egr-1 siRNA eluted from dopamine-coated surfaces, significantly reduced the proliferation of HAoSMCs and their protein expression of Egr-1. Therefore, this method of surface immobilization of siRNA onto dopamine-coated surfaces might be effective for nucleic acid delivery from stents.


Subject(s)
Dopamine/chemistry , RNA, Small Interfering/administration & dosage , Stainless Steel , HeLa Cells , Humans , Surface Properties
9.
Biomed Res Int ; 2013: 265980, 2013.
Article in English | MEDLINE | ID: mdl-24459666

ABSTRACT

Titanium was treated with 3,4-dihydroxy-L-phenylalanine (DOPA) or dopamine to immobilize bone morphogenetic protein-2 (BMP2), a biomolecule. DOPA and dopamine solutions turned into suspensions, and precipitates were produced at high pH. Both treatments produced a brown surface on titanium that was thicker at high pH than low pH. Dopamine produced a thicker layer than DOPA. The hydrophobicity of the surfaces increased after treatment with dopamine independent of pH. Furthermore, there were more amino groups in the layers formed at pH 8.5 than pH 4.5 in both treatments. Dopamine treatment produced more amino groups in the layer than DOPA. BMP2 was immobilized on the treated surfaces via a coupling reaction using carbodiimide. More BMP2 was immobilized on surfaces treated at pH 8.5 than pH 4.5 in both treatments. The immobilized BMP induced specific signal transduction and alkali phosphatase, a differentiation marker. Thus, the present study demonstrates that titanium treated with DOPA or dopamine can become bioactive via the surface immobilization of BMP2, which induces specific signal transduction.


Subject(s)
Bone Morphogenetic Protein 2/chemistry , Immobilized Proteins/chemistry , Osseointegration/drug effects , Titanium/chemistry , Animals , Bone Morphogenetic Protein 2/metabolism , Cell Adhesion/drug effects , Cell Differentiation/drug effects , Cell Line , Coated Materials, Biocompatible/chemistry , Dihydroxyphenylalanine/pharmacology , Dopamine/pharmacology , Immobilized Proteins/metabolism , Mice , Surface Properties
10.
Acta Biomater ; 6(10): 4005-10, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20580950

ABSTRACT

A novel visible light-crosslinkable porcine gelatin was prepared for gelation and micropatterning. The preparation employed a photo-oxidation-induced crosslinking mechanism. First, furfuryl groups were incorporated into the gelatin. Second, the modified gelatin was mixed in water with Rose Bengal, which is a visible light sensitizer. Irradiation by visible light solidified the aqueous solution. In addition, when the solution was cast on a plate, dried and photo-irradiated in the presence of a photomask a micropattern was formed that matched the micropattern on the photomask. The gelatin-immobilized regions enhanced cell adhesion. It was also confirmed that the gelatin incorporating furfuryl and Rose Bengal have no significant toxicity. The photo-crosslinkable gelatin was employed as a direct pulp capping material in the dental field. Considering these results, this system could be useful as a new type of visible light-induced crosslinkable biosealant.


Subject(s)
Gelatin , Light , Photochemistry/methods , Animals , Biocompatible Materials/chemistry , Biocompatible Materials/radiation effects , Cell Culture Techniques/methods , Cell Line , Cross-Linking Reagents/chemistry , Dental Pulp/cytology , Dental Pulp/metabolism , Fluorescent Dyes/chemistry , Gelatin/chemistry , Gelatin/radiation effects , Materials Testing , Mice , Molecular Structure , Pulp Capping and Pulpectomy Agents/chemistry , Pulp Capping and Pulpectomy Agents/radiation effects , Rats , Rose Bengal/chemistry , Swine
11.
J Microbiol Biotechnol ; 20(2): 433-7, 2010 Feb.
Article in English | MEDLINE | ID: mdl-20208452

ABSTRACT

In the course of our screening for novel modulators on cell cycle progression and apoptosis as anticancer drug candidates, we generated an analogue of sangivamycin, MCS-C2, designated as 4-amino-6-bromo-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide. This study was aimed to evaluate the molecular mechanisms on cell cycle arrest and apoptotic induction of MCS-C2 in human lung cancer A549 cells. To investigate the effects of MCS-C2 on cell cycle progression in A549 cells, we measured DNA content of A549 cells treated with 5 microM of HY253 using flow cytometric analysis. The flow cytometric analysis revealed an appreciable G(2) phase arrest in A549 cells treated with 5 micronM of MCS-C2. This MCS-C2-induced G(2) phase arrest is associated with significant up-regulation of p53 and p21(Cip1) in A549 cells. Furthermore, TUNEL assay was used to examine apoptotic induction in A549 cells treated with 5 microM of MCS-C2 for 48 h. In addition, the effects of MCS-C2 on apoptosis-associated proteins in A549 cells were examined using Western blot analysis. The apoptotic induction in MCS-C2-treated A549 cells is associated with cytochrome c release from mitochondria which in turn resulted in the activation of caspase-9 and -3, and the cleavage of poly(ADP-ribose) polymerase (PARP). In conclusion, based on these results, we suggest that MCS-C2 may be a potent cancer chemotherapeutic candidate for use in treating human lung cancer cells via up-regulation and activation of p53.


Subject(s)
Apoptosis/drug effects , Cell Cycle/drug effects , Cytochromes c/metabolism , Lung Neoplasms/physiopathology , Toyocamycin/analogs & derivatives , Cell Line, Tumor , Humans , Lung Neoplasms/drug therapy , Lung Neoplasms/metabolism , Pyrimidine Nucleosides/pharmacology , Toyocamycin/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...